Derfor besluttede udvalget, at fordelene ved HBVAXPRO er større end risiciene i forbindelse med aktiv immunisering imod hepatitis B- virusinfektion, som skyldes alle kendte undertyper hos mennesker, som anses for at have en risiko for at blive eksponeret for hepatitis B- virus.
Therefore, the Committee decided that HBVAXPRO’ s benefits are greater than its risks for active immunisation against hepatitis B virus infection caused by all known subtypes in people considered at risk of exposure to hepatitis B virus.